
BCAX Stock Forecast & Price Target
BCAX Analyst Ratings
Bulls say
Bicara Therapeutics Inc. is positioned positively within the clinical-stage biopharmaceutical landscape due to the efficacy of its proprietary ficerafusp alfa therapy, which showcases a meaningful improvement in objective response rates when compared to existing treatments like Keytruda. Specifically, ficerafusp alfa, in combination with Keytruda, demonstrated a median progression-free survival (mPFS) of 9.9 months and a median overall survival (mOS) of 21.3 months, notably exceeding prevailing metrics in similar patient populations. This compelling data suggests that Bicara's innovative bifunctional antibody approach could offer significant advantages over current therapies, underscoring a bullish outlook for the company's stock.
Bears say
Bicara Therapeutics Inc reported a net loss of $0.50 per share for the second quarter of 2025, consistent with prior estimates, indicating ongoing financial challenges. The company's outlook is further complicated by substantial risks, including the potential for negative clinical results with its lead therapy ficerafusp alfa, delays in progressing to registrational trials, and competitive pressures from other bispecific therapies in development. Additionally, there is a significant risk of long-term dilution which could inhibit shareholder value, reinforcing concerns about the company's financial viability moving forward.
This aggregate rating is based on analysts' research of Bicara Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
BCAX Analyst Forecast & Price Prediction
Start investing in BCAX
Order type
Buy in
Order amount
Est. shares
0 shares